💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling business — but flagged on governance.
Dishman Carbo is scored on the pharma / healthcare framework. It keeps a thin 3.3% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 5.04× reported profit. It throws off free cash worth 10.0% of its market value — a strong free-cash yield.
Book value has grown 5%/yr. Return on equity is a weak 1.5%. In the latest quarter profit fell 366% versus the prior quarter.
It trades at 152× earnings. Today's price already implies ~37%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises a red flag: 53% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 152.28 | — | — |
| P/B | 0.37 | — | — |
| EV/EBITDA | 8.57 | 19.33 | better |
| ROE | 1.46 | 0.3 | better |
| ROCE | 2.66 | 14.41 | worse |
| ROA | 0.14 | — | — |
| Quick Ratio | 0.79 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 7% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
2 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a +2908% swing — check if it's a one-off or structural.
Operating margin has expanded from -2% to 4% — the business is keeping more of each rupee earned.
ROE at 1% — modest; the capital isn't working hard.
Profit grew faster than EPS (2908% vs 2862%) — share dilution is eroding per-share value. 2862% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 5.0× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 20% QoQ — could be seasonality or a genuine slowdown. Run-rate stepping up — recent quarters average 13% above earlier ones.
2 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 366% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (10% → -8%) — more revenue isn't translating to proportionally more profit.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoter holding at 59.3% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.